Browse
Submit Data
Databases
API
Help

Dataset Information

21 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Population screening for colorectal cancer by colonoscopy or CT-colonography in the Netherlands.

ABSTRACT: Interventions: For this study, 7500 persons will be invited and randomized (1:1:1) in three different arms: 1. CT-colonography (2500 individuals); 2. Colonoscopy and preliminary interview by phone (2500 individuals); 3. Colonoscopy and preliminary interview at outpatient clinic (2500 individuals). Furthermore, an extra number of 10.000 persons will be randomized for the NORDICC trial (this trial will be registered separately). These persons will not be invited to participate in the screening program. The primary outcome of this study is the participation rate. The expected participation rate for the respective separate arms is 35 %, 27,5 % and 22,5 %. Consequently, a total number of 1250 colonoscopies and 875 CT-colonographies is expected. To allow sufficient certainty, we will continue the study until the target number of 1250 colonoscopies and 875 CT-colonographies is reached. Primary outcome(s): Evaluation of the participation rate of a population-based screening program by colonoscopy or CT-colonography in the Netherlands. Study Design: Randomized controlled trial, Open (masking not used), Active, Parallel

DISEASE(S): Colorectal Cancer, Adenomatous Polyps, Screening, Colonoscopy, Ct-colonography

PROVIDER: 16140 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Evaluation of a standardized CT colonography Training Program

Project description:Primary outcome(s): The number of CT colonography examinations for sufficient sensitivity and specifity

| 2639308 | ecrin-mdr-crc

Effect of treatment for three months with chemical carcinogen and non-carcinogens on liver miRNAome

Project description:Here, we examined the liver microRNA profile of male Fischer rats exposed through their diet to genotoxic (2-acetylaminofluorene) and epigenetic (phenobarbital, diethylhexylphthalate, methapyrilene HCL, monuron, and chlorendic acid) chemical hepatocarcinogens, as well as to non-hepatocarcinogenic treatments (benzophenone, and diethylthiourea) for three months. The aim of the study was to investigate how liver miRNA profiles relate to mode of action and carcinogenic potential of chemicals. In total miRNA profiles from 38 liver samples were examined. These included 3-5 samples for animal fed control diets or diet supplemented with designated chemicals. For each chemical a carcinogenic or a maximum tolerated dose was chosen based on published literature. The treatments were Diethylthiourea (DETU) 2500 ppm; Benzophenone (BP) 1250 ppm ; Monuron (MON) 1500 ppm ; Diethylhexylphthalate (DEHP) 12000 ppm ; Phenobarbital (PB) 1000 ppm; Chlorendic acid (CA) 1250 ppm; Methapyrilene HCl (MP) 250 ppm; 2-Acetyl aminofluorene (2-AAF) 40 ppm.

2013-07-03 | E-GEOD-48492 | biostudies-arrayexpress

Immunochemical FOBT screening for colorectal cancer: yield and attendance for one- versus two-sample tests, and for second round screening with various intervals.

Project description:Interventions: 1-sample or 2-samples immunochemical FOBTs. Firstly, a representative population sample of 2.500 asymptomatic persons between 50-75 years of age in the region ‘Rijnmond’ will be invited for the 1st screening round using 1-sample iFOBT in 2008 and for a 2nd screening round after one year (group A). Secondly, the 5.000 asymptomatic persons who were invited in our first trial for a 1st-round one-sample iFOBT in 2006/2007 (NTR = 1096), will be invited for 2nd round screening. They will be pre-randomized for biennial (group B) or triennial (group C) 2nd round screening. The attendance rate of these two groups will be compared with the participation of the second screening round from group A. Furthermore, 3.200 newly randomly selected persons will be invited for a single 1st round screening using 2-sample iFOBT (group D). The attendance rate of this group will be compared with the participation of the first screening round from group A. Primary outcome(s): Adherence for second round CRC screening with 1-sample iFOBT (OC-Hemodia Latex) comparing annual, biennial, and triennial screening interval. Adherence and diagnostic yield of a first screening round comparing 1-sample versus 2-sample iFOBT screening. Study Design: Randomized controlled trial, Open (masking not used), N/A , unknown, Parallel

| 15872 | ecrin-mdr-crc

To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations

Project description:Intervention1: Capecitabine Tablets 500 mg, manufactured by Hetero labs ltd.: The recommended dose of capacitabine is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Intervention2: Capecitabine Tablets 500 mg,manufactured by Hetero labs ltd.: The recommended dose of capacitabine is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Control Intervention1: XelodaÂ (Capecitabine) Tablets 500 mg (Distributed by Genentech USA, Inc., A Member of the Roche Group, South San Francisco, CA 94080): The recommended dose of XELODAÂ is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Primary outcome(s): Establishing the bioequivalence between test and referenceTimepoint: Day 1 and Day 2

| 2573933 | ecrin-mdr-crc

Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): 3 round.

Project description:Interventions: For this study, 10.000 individuals will be invited for CRC screening by FIT (OC-sensor). Primary outcome(s): Participation rate. Study Design: N/A: single arm study, Open (masking not used), N/A , unknown, Parallel

| 17029 | ecrin-mdr-crc

Yield and burden of surveillance CT colonography in a population screening trial for colorectal cancer.

Project description:Interventions: 1. Surveillance CT colonography; 2. Pre- and post- procedural questionnaires; 3. Pain assessment during CT colonography. Primary outcome(s): The final CT colonography screening yield for advanced neoplasia per 100 invitees through determining surveillance CT colonography yield. Study Design: N/A: single arm study, Open (masking not used), N/A , unknown, Parallel

| 17804 | ecrin-mdr-crc

To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations.

Project description:Intervention1: Capecitabine Tablets 500 mg, manufactured by Hetero labs ltd.: The recommended dose of capacitabine is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Control Intervention1: XelodaÂ (Capecitabine) 500mg film coated tablet, manufactured by Roche Pharma AG, Emil-Barell Str I, D-79639 Grenzach-Wyhlen, Duitsland: The recommended dose of XELODAÂ is 1250 mg/m2 administered orally twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 2 weeks followed by a 1-week rest period given as 3 week cycles Primary outcome(s): Establishing the bioequivalence between test and referenceTimepoint: Day 1 and Day 2

| 2573796 | ecrin-mdr-crc

Age-associated changes in human CD4+ T cells point to mitochondrial dysfunction consequent to impaired autophagy

Project description:To gain understanding on the mechanisms that drive immunosenescence in humans, we examined CD4+ T cells obtained from younger (20-39 years-old) and older (70+ years-old) healthy participants of the Baltimore Longitudinal Study on Aging (BLSA). We found that mitochondrial proteins involved in the electron transport chain were overrepresented in cells from older participants, with prevalent dysregulation of oxidative phosphorylation and energy metabolism molecular pathways. Surprisingly, gene transcripts coding for mitochondrial proteins pertaining to oxidative phosphorylation and electron transport chain pathways were underrepresented in older individuals. Paralleling the observed decrease in gene expression, mitochondrial respiration was impaired in CD4+ T cells from older subjects. Though mitochondrial number in both naïve and memory cells visualized with electron microcopy was similar in older versus younger participants, there were a significantly higher number of autophagosomes, many of them containing undegraded mitochondria, in older individuals. The presence of mitochondria inside the accumulated autophagic compartments in CD4+ T cells from older individuals was confirmed by immunofluorescence. These findings suggest that older age is associated with persistence of dysfunctional mitochondria in CD4+ T lymphocytes caused by defective mitochondrial turnover by autophagy, which may trigger chronic inflammation and contribute to the impairment of immune defense in older persons.

2019-11-27 | PXD016039 | Pride

Open-label randomizsed comparative study of the detection rates of colorectal tumors/polyps between colon capsule endoscopy and CT colonography

Project description:Interventions: colon capsule endoscopy CT colonography Primary outcome(s): Sensitivity and specificity of colon capsule and CT colonography for colorectal tumors/polyps Study Design: Parallel Randomized

| 2628101 | ecrin-mdr-crc

RNA-seq analysis of MCF7 xenografts after treatment with OP-1250 and/or CDK4/6 inhibitors palbociclib or ribociclib

Project description:The estrogen receptor (ER) is a well-established target for the treatment of breast cancer, with the majority of patients presenting as ER-positive (ER+). Endocrine therapy is a mainstay of breast cancer treatment but the development of resistance mutations in response to aromatase inhibitors, poor pharmacokinetic properties of fulvestrant, agonist activity of tamoxifen, and limited benefit for elacestrant leave unmet needs for patients with or without resistance mutations in ESR1, the gene that encodes the ER protein. Here we describe OP-1250, a novel, orally bioavailable complete ER antagonist and selective ER degrader. OP-1250, like fulvestrant, has no agonist activity on the ER and completely blocks estrogen-induced transcriptional activity. In addition, OP-1250 demonstrates favorable biochemical binding affinity, ER degradation, and antiproliferative activity in ER+ breast cancer models that is comparable or superior to other agents of interest. OP-1250 has superior pharmacokinetic properties relative to fulvestrant, including oral bioavailability and brain penetrance, as well as superior performance in wild-type and ESR1-mutant breast cancer xenograft studies. OP-1250 combines well with cyclin-dependent kinase 4 and 6 inhibitors in xenograft studies of ER+ breast cancer models and effectively shrinks intracranially implanted tumors, resulting in prolonged animal survival. With demonstrated preclinical efficacy exceeding fulvestrant in wild-type models, elacestrant in ESR1-mutant models, and tamoxifen in intracranial xenografts, OP-1250 has the potential to benefit patients with ER+ breast cancer.

2023-09-01 | GSE241943 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data